April 05, 2013
2 min read

1,25-dihydroxyvitamin D linked to poorer bone health in men

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Study researchers from the European Male Aging Study group recently reported that serum 1,25-dihydroxyvitamin D is associated with a higher bone turnover and poorer bone health in middle-aged and older European men.

Men aged 40 to 79 years (n=2,783) from population registries at eight European centers completed questionnaires regarding lifestyle and measurements of quantitative ultrasound (QUS) of the heel, in addition to assessments for height and weight.

Further measurements included: 1,25-(OH)2D, 25-(OH)D, parathyroid hormone (PTH), bone markers serum N-terminal propeptide of type 1 procollagen (P1NP) and cross links (beta-cTX). In two of the centers, DXA of the hip and lumbar spine was conducted.

After adjustments for age and center, data indicate that 1,25-(OH)2D was positively associated with 25-(OH)D but not with PTH. Conversely, 25-(OH)D was negatively associated with PTH. After further adjustments, researchers wrote that 1,25-(OH)2D was negatively associated with QUS and DXA parameters, but positively with beta-cTX. However, 1,25-(OH)2D was not correlated with P1NP.

Moreover, 25-(OH)D was positively associated with the QUS and DXA parameters but not related to either bone turnover marker, the researchers wrote. Patients with high 1,25-(OH)2D (upper tertile) and low 25-(OH)D (lower tertile) had the lowest QUS and DXA parameters and the highest beta-cTX levels, according to data.

“These results contribute to the understanding of the influence of 1,25-(OH)2D on bone health in middle-aged and elderly men,” the researchers wrote.

Disclosure: The researchers report no relevant financial disclosures.